James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

4 Stocks That Could Crash in 2015

GlaxoSmithKline (GSK), Herbalife (HLF), BlackBerry (BBRY) and RadioShack (RSH) could end up being the worst of the worst this year.

British Banks Erroneously Balk at Apple Pay

Investors of Britain's bank stocks need not fear Apple Pay as much as they're being led to believe.

Why SolarCity, Globalstar and Corrections Corp. Are 3 of Today’s Worst Stocks

SolarCity, Globalstar and Corrections Corp. of America were the worst of the worst on Tuesday, though for understandable reasons.

Why Palo Alto Networks, Arista Networks and GoPro Are 3 of Today’s Worst Stocks

Palo Alto Networks, Arista Networks and GoPro led the bearish charge today, even without any news behind the selloffs.

Add Roche to Your List of Ebola Stocks, But …

Ebola stocks have doled out some big gains to savvy traders this year, but investors looking for Roche (RHHBY) to do the same may want to rethink their expectations.